Phase 1 Study of Macrophage Reprogramming Agent, exoASO-STAT6 (CDK-004), in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From Either Primary Gastric Cancer or Colorectal Cancer (CRC)

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 05 Jun 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ExoASO STAT6 (Primary)
Indications Cancer; Colorectal cancer; Gastric cancer; Liver cancer; Liver metastases
Focus Adverse reactions; First in man
Sponsors Codiak BioSciences

Most Recent Events

30 May 2023 Status changed from active, no longer recruiting to discontinued.
29 Mar 2023 Status changed from recruiting to active, no longer recruiting.
29 Jun 2022 According to a Codiak BioSciences media release, patients dosing has been initiated in this study. The company expects data from this study in the first half of 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight